Corbus Pharmaceuticals Holdings, Inc.

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
37.04 ^USD	+3.93%		-1.85%	+513.25%

12:00am	Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI
12:00am	Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

February 06, 2024 at 04:13 pm EST

Corbus Pharmaceuticals Holdings, Inc. announced the resignation of Rachael Brake, Ph.D., as Chief Scientific Officer . The effective date of Dr. Brake?s resignation will be February 19, 2024.

Latest news about Corbus Pharmaceuticals Holdings, Inc.

Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	2024-04-30	CI
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	2024-04-30	CI
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	2024-04-30	CI
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	2024-04-30	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	Apr. 02	CI
Corbus Pharmaceuticals Files Mixed Shelf	Mar. 13	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating	Mar. 13	MT
Health Care Climbs on Risk Appetite -- Health Care Roundup	Mar. 12	DJ
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold	Mar. 06	MT
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer	Feb. 28	CI
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024	Feb. 06	CI
Corbus Pharmaceuticals Closes $94.5 Million Public Offering	Feb. 02	MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating	Jan. 29	MT
Top Premarket Decliners	Jan. 29	MT
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Sector Update: Health Care	Jan. 26	MT
Top Midday Gainers	Jan. 26	MT
Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701	Jan. 26	CI
Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)	Jan. 09	CI
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $20 From $22, Maintains Outperform Rating	Nov. 08	MT
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI

Chart Corbus Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Corbus Pharmaceuticals Holdings, Inc.

More charts

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFÎ² expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.04 USD

Average target price

55 USD

Spread / Average Target

+48.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CORBUS PHARMACEUTICALS HOLDINGS, INC.	+513.25%	389M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.33%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs